Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion
In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination piperacillin–tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, th...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2005, Vol.25 (1), p.62-67 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | 1 |
| container_start_page | 62 |
| container_title | International journal of antimicrobial agents |
| container_volume | 25 |
| creator | Buck, Christine Bertram, Norbert Ackermann, Thomas Sauerbruch, Tilman Derendorf, Hartmut Paar, Wilhem Dieter |
| description | In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination piperacillin–tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0
μg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3
μg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose. |
| doi_str_mv | 10.1016/j.ijantimicag.2004.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67346244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857904003486</els_id><sourcerecordid>67346244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-bd59fc17100b2c04b41655bdf480a26b78c54b98b3c62695004a3e459620bf043</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxi0EokvhFVA4wC2p7diOzQ2t-CdVoodyRJbtOGWWxF5spxKc-g68IU-CV7tSucFp5vCbme-bD6EXBHcEE3Gx62BnQoEFnLnpKMasw7LDhD5AGyIH2g6K9A_RBivKWskHdYae5LzDmPCe8cfojHBBsaRyg75cfTVpMS5-g-ALuNzEqdnD3ifjYJ4h_L77VczPaI0rZnndQCg-LVCKD6UZY4Zw09z6lNfcuFglhTXWFsK0ZojhKXo0mTn7Z6d6jj6_e3u9_dBefnr_cfvmsnWsF6W1I1eTIwPB2FKHmWVEcG7HiUlsqLCDdJxZJW3vBBWKV8Om94yr6sJOmPXn6NVx7z7F76vPRS-QnZ9nE3zVo8XQM0HZv0EyDEqwnldQHUGXYs7JT3qfYDHphyZYH0LQO_1XCPoQgsZS1xDq7PPTkdUufryfPH29Ai9PgMnOzFMywUG-50Q_SIUPIrZHztff3YJPOjvwwfkRkndFjxH-Q84fPiWt2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17796435</pqid></control><display><type>article</type><title>Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Buck, Christine ; Bertram, Norbert ; Ackermann, Thomas ; Sauerbruch, Tilman ; Derendorf, Hartmut ; Paar, Wilhem Dieter</creator><creatorcontrib>Buck, Christine ; Bertram, Norbert ; Ackermann, Thomas ; Sauerbruch, Tilman ; Derendorf, Hartmut ; Paar, Wilhem Dieter</creatorcontrib><description>In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination piperacillin–tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0
μg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3
μg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2004.08.012</identifier><identifier>PMID: 15620828</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Adult ; Aged ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacokinetics ; Anti-Bacterial Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobial therapy ; Biological and medical sciences ; Cholangitis - drug therapy ; Community-Acquired Infections - drug therapy ; Continuous infusion ; Cross Infection - drug therapy ; Drug Administration Schedule ; Female ; Fever of Unknown Origin - drug therapy ; Hospitalization ; Humans ; Infection - drug therapy ; Infection - etiology ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Penicillanic Acid - administration & dosage ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - pharmacokinetics ; Penicillanic Acid - therapeutic use ; Pharmacology. Drug treatments ; Piperacillin ; Piperacillin - administration & dosage ; Piperacillin - pharmacokinetics ; Piperacillin - therapeutic use ; Pneumonia - drug therapy ; Prospective Studies ; Tazobactam ; Treatment Outcome ; Urinary Tract Infections - drug therapy ; β-Lactam antibiotics</subject><ispartof>International journal of antimicrobial agents, 2005, Vol.25 (1), p.62-67</ispartof><rights>2004 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-bd59fc17100b2c04b41655bdf480a26b78c54b98b3c62695004a3e459620bf043</citedby><cites>FETCH-LOGICAL-c436t-bd59fc17100b2c04b41655bdf480a26b78c54b98b3c62695004a3e459620bf043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2004.08.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16378905$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15620828$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buck, Christine</creatorcontrib><creatorcontrib>Bertram, Norbert</creatorcontrib><creatorcontrib>Ackermann, Thomas</creatorcontrib><creatorcontrib>Sauerbruch, Tilman</creatorcontrib><creatorcontrib>Derendorf, Hartmut</creatorcontrib><creatorcontrib>Paar, Wilhem Dieter</creatorcontrib><title>Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination piperacillin–tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0
μg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3
μg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobial therapy</subject><subject>Biological and medical sciences</subject><subject>Cholangitis - drug therapy</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Continuous infusion</subject><subject>Cross Infection - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fever of Unknown Origin - drug therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infection - drug therapy</subject><subject>Infection - etiology</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - administration & dosage</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - pharmacokinetics</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperacillin</subject><subject>Piperacillin - administration & dosage</subject><subject>Piperacillin - pharmacokinetics</subject><subject>Piperacillin - therapeutic use</subject><subject>Pneumonia - drug therapy</subject><subject>Prospective Studies</subject><subject>Tazobactam</subject><subject>Treatment Outcome</subject><subject>Urinary Tract Infections - drug therapy</subject><subject>β-Lactam antibiotics</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQxi0EokvhFVA4wC2p7diOzQ2t-CdVoodyRJbtOGWWxF5spxKc-g68IU-CV7tSucFp5vCbme-bD6EXBHcEE3Gx62BnQoEFnLnpKMasw7LDhD5AGyIH2g6K9A_RBivKWskHdYae5LzDmPCe8cfojHBBsaRyg75cfTVpMS5-g-ALuNzEqdnD3ifjYJ4h_L77VczPaI0rZnndQCg-LVCKD6UZY4Zw09z6lNfcuFglhTXWFsK0ZojhKXo0mTn7Z6d6jj6_e3u9_dBefnr_cfvmsnWsF6W1I1eTIwPB2FKHmWVEcG7HiUlsqLCDdJxZJW3vBBWKV8Om94yr6sJOmPXn6NVx7z7F76vPRS-QnZ9nE3zVo8XQM0HZv0EyDEqwnldQHUGXYs7JT3qfYDHphyZYH0LQO_1XCPoQgsZS1xDq7PPTkdUufryfPH29Ai9PgMnOzFMywUG-50Q_SIUPIrZHztff3YJPOjvwwfkRkndFjxH-Q84fPiWt2Q</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Buck, Christine</creator><creator>Bertram, Norbert</creator><creator>Ackermann, Thomas</creator><creator>Sauerbruch, Tilman</creator><creator>Derendorf, Hartmut</creator><creator>Paar, Wilhem Dieter</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion</title><author>Buck, Christine ; Bertram, Norbert ; Ackermann, Thomas ; Sauerbruch, Tilman ; Derendorf, Hartmut ; Paar, Wilhem Dieter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-bd59fc17100b2c04b41655bdf480a26b78c54b98b3c62695004a3e459620bf043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobial therapy</topic><topic>Biological and medical sciences</topic><topic>Cholangitis - drug therapy</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Continuous infusion</topic><topic>Cross Infection - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fever of Unknown Origin - drug therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infection - drug therapy</topic><topic>Infection - etiology</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - administration & dosage</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - pharmacokinetics</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperacillin</topic><topic>Piperacillin - administration & dosage</topic><topic>Piperacillin - pharmacokinetics</topic><topic>Piperacillin - therapeutic use</topic><topic>Pneumonia - drug therapy</topic><topic>Prospective Studies</topic><topic>Tazobactam</topic><topic>Treatment Outcome</topic><topic>Urinary Tract Infections - drug therapy</topic><topic>β-Lactam antibiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buck, Christine</creatorcontrib><creatorcontrib>Bertram, Norbert</creatorcontrib><creatorcontrib>Ackermann, Thomas</creatorcontrib><creatorcontrib>Sauerbruch, Tilman</creatorcontrib><creatorcontrib>Derendorf, Hartmut</creatorcontrib><creatorcontrib>Paar, Wilhem Dieter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buck, Christine</au><au>Bertram, Norbert</au><au>Ackermann, Thomas</au><au>Sauerbruch, Tilman</au><au>Derendorf, Hartmut</au><au>Paar, Wilhem Dieter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2005</date><risdate>2005</risdate><volume>25</volume><issue>1</issue><spage>62</spage><epage>67</epage><pages>62-67</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination piperacillin–tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0
μg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3
μg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>15620828</pmid><doi>10.1016/j.ijantimicag.2004.08.012</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2005, Vol.25 (1), p.62-67 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67346244 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobial therapy Biological and medical sciences Cholangitis - drug therapy Community-Acquired Infections - drug therapy Continuous infusion Cross Infection - drug therapy Drug Administration Schedule Female Fever of Unknown Origin - drug therapy Hospitalization Humans Infection - drug therapy Infection - etiology Infusions, Intravenous Male Medical sciences Middle Aged Penicillanic Acid - administration & dosage Penicillanic Acid - analogs & derivatives Penicillanic Acid - pharmacokinetics Penicillanic Acid - therapeutic use Pharmacology. Drug treatments Piperacillin Piperacillin - administration & dosage Piperacillin - pharmacokinetics Piperacillin - therapeutic use Pneumonia - drug therapy Prospective Studies Tazobactam Treatment Outcome Urinary Tract Infections - drug therapy β-Lactam antibiotics |
| title | Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20piperacillin%E2%80%93tazobactam:%20intermittent%20dosing%20versus%20continuous%20infusion&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Buck,%20Christine&rft.date=2005&rft.volume=25&rft.issue=1&rft.spage=62&rft.epage=67&rft.pages=62-67&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2004.08.012&rft_dat=%3Cproquest_cross%3E67346244%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17796435&rft_id=info:pmid/15620828&rft_els_id=S0924857904003486&rfr_iscdi=true |